CClinicalTrials.gg
Not yet recruitingNCT07748221ONCO-MinDUpdated Sep 16, 2026

Healthcare Providers' Attitudes Toward Oncology Patients With Mental Disorders

An observational study in Stigma of Mental Illness, Cancer and Psychiatric Comorbidity, sponsored by Istituto Oncologico Veneto IRCCS. Not yet recruiting at 3 sites in Italy. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Istituto Oncologico Veneto IRCCS · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,000
Sex
All
01

Study summary

ONCO-MinD is a multicentre, cross-sectional, non-interventional mixed-method study aimed at investigating healthcare providers' attitudes towards oncology patients with mental disorders in Italian cancer centres. The study will assess levels of mental health-related stigma among healthcare professionals and explore factors associated with these attitudes, including professional background, clinical setting, experience, and previous exposure to mental health conditions. Quantitative survey data collected using the Italian version of the Opening Minds Scale for Health Care Providers (OMS-HC) will be integrated with qualitative findings from semi-structured interviews to provide a comprehensive understanding of how stigma may influence clinical relationships, decision-making processes, and equity of cancer care.

Read the detailed description

Background People living with mental disorders experience substantial health inequalities, including reduced life expectancy and higher mortality rates from physical illnesses, including cancer. In oncology settings, evidence suggests that patients with mental disorders are less likely to receive guideline-concordant treatment, are more likely to experience delays in diagnosis, and often have lower treatment adherence. Multiple factors contribute to these disparities, including patient-related, organisational, and healthcare provider-related determinants.

Among healthcare provider-related factors, stigma towards people with mental disorders may influence communication, therapeutic relationships, treatment decisions, and access to appropriate care. One particularly relevant mechanism is diagnostic overshadowing, whereby physical symptoms may be misattributed to a patient's psychiatric condition, potentially resulting in delayed diagnosis and suboptimal management. Despite growing recognition of these issues, limited evidence is available regarding stigma among oncology healthcare professionals, particularly within the Italian context.

Study Objectives The primary objective is to evaluate the level of stigma among healthcare professionals towards oncology patients with mental disorders.

Secondary objectives are:

To identify associations between stigma levels and individual or professional characteristics, including years of experience, professional role, clinical area, education, and previous personal or professional exposure to mental health conditions.

To explore healthcare professionals' experiences, perceptions, and attitudes towards caring for oncology patients with mental disorders.

To investigate potential barriers affecting clinical interactions and care pathways, including the role of diagnostic overshadowing and other stigma-related mechanisms.

Study Design

ONCO-MinD is a multicentre, observational, cross-sectional, non-interventional study using a sequential explanatory mixed-method design. The study consists of two consecutive and integrated phases:

Phase 1: Quantitative Component

Eligible healthcare professionals working in participating oncology centres will be invited to complete an anonymous electronic questionnaire through a secure REDCap platform. The questionnaire includes:

Socio-demographic and professional characteristics. The Italian version of the Opening Minds Scale for Health Care Providers (OMS-HC), a validated instrument measuring stigma towards individuals with mental disorders.

The survey will remain available for approximately three months. Phase 2: Qualitative Component Following analysis of the quantitative findings, a purposive sample of healthcare professionals will be invited to participate in semi-structured interviews. Interviews will explore experiences, perceptions, barriers, facilitators, and the impact of mental health conditions on oncology care and clinical decision-making. Interviews will be audio-recorded, transcribed, anonymised, and analysed using thematic analysis.

Integration of Findings Quantitative and qualitative results will be integrated through a mixed-method approach using joint displays and meta-inferences. This strategy will allow a deeper understanding of the factors underlying stigma and its potential influence on cancer care delivery.

Study Population

The study population includes healthcare professionals directly involved in oncology care at participating centres, including:

Physicians Nurses Psychologists Radiation therapy technologists Healthcare assistants

All eligible professionals working within participating institutions will be invited to participate.

Participating Centres

Veneto Institute of Oncology (IOV-IRCCS), Padua, Italy Centro di Riferimento Oncologico (CRO-IRCCS), Aviano, Italy Istituto Tumori "Giovanni Paolo II" (IRCCS), Bari, Italy

Expected Impact The study is expected to generate evidence on mental health-related stigma in oncology settings and to identify educational and organisational strategies that may improve equity, inclusiveness, and quality of cancer care for patients living with mental disorders.

02

Conditions studied

  • Stigma of Mental Illness
  • Cancer
  • Psychiatric Comorbidity

Keywords

  • oncology
  • cancer
  • mental health
  • stigma
  • psychiatric comorbidity
  • oncology healthcare professionals
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of healthcare professionals working in oncology settings at participating Italian cancer centres. Eligible participants include physicians, nurses, psychologists, radiation therapy technologists, and healthcare assistants directly involved in the care of oncology patients. Participants will be recruited through exhaustive sampling across participating institutions and invited to complete an anonymous survey. A purposive sample of survey participants may subsequently be invited to participate in semi-structured interviews as part of the qualitative phase of the study.

Inclusion criteria

  • Healthcare professionals working in participating oncology centres.
  • Physicians, nurses, psychologists, radiation therapy technologists, and healthcare assistants.
  • Direct involvement in the clinical care of oncology patients.
  • Employed at one of the participating study sites at the time of enrolment.
  • Able to understand the study information and provide informed consent.
  • Willing to participate in the study.

For the qualitative phase, a purposive sample of participants will be selected from survey respondents who agree to be contacted for a semi-structured interview.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate or failure to provide informed consent.
  • Students in training.
  • Healthcare personnel working in services with very limited patient contact and without direct responsibility for oncology patient care.
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Oncology Healthcare Professionals

    Physicians, nurses, psychologists, radiation therapy technologists, and healthcare assistants working in participating oncology centres.

    Other: OMS-HC Questionnaire and Semi-Structured Interviews

Interventions

  • OtherOMS-HC Questionnaire and Semi-Structured Interviews

    Participants complete an anonymous questionnaire and, where selected, participate in a semi-structured interview for research data collection purposes. No clinical or behavioural intervention is administered.

05

What researchers measure

Primary outcomes

  1. Mental health-related stigma among oncology healthcare professionals

    Level of stigma towards people with mental disorders measured using the Italian version of the Opening Minds Scale for Health Care Providers (OMS-HC). The total score ranges from 15 to 75, with higher scores indicating greater stigma and lower scores indicating more positive attitudes towards people with mental disorders.

    Time frame: At survey completion (up to 3 months)

Secondary outcomes

  1. Factors Associated With OMS-HC Scores

    Association between OMS-HC scores and healthcare professionals' socio-demographic and professional characteristics, including age, sex, professional role, education, clinical area, years of experience, previous mental health experience, and perceived mental health training.

    Time frame: Up to 3 months

  2. Healthcare professionals' experiences and perceptions regarding oncology patients with mental disorders

    Qualitative themes identified through semi-structured interviews, including perceived barriers to care, diagnostic overshadowing, impact of psychiatric comorbidity on clinical decision-making, relational challenges, and facilitators to improve cancer care.

    Time frame: Up to 9 months

  3. Integrated mixed-method understanding of stigma towards oncology patients with mental disorders

    Integration of quantitative survey findings and qualitative interview data through joint displays and meta-inferences to provide a comprehensive understanding of mental health-related stigma among oncology healthcare professionals, including its determinants, manifestations, and perceived impact on cancer care delivery and clinical decision-making.

    Time frame: Up to 13 months

06

Study locations

3 sites
  • Centro Riferimento Oncologico CRO IRCCS
    Aviano, 33081, Italy
  • Istituto Tumori IRCCS Giovanni Paolo II
    Bari, 70124, Italy
  • The Padua, Castelfranco Veneto, and Schiavonia campuses of the Veneto Institute of Oncology (IOV-IRCCS).
    Padova, 35128, Italy
    • Carlo Alberto Camuccio, MSN; MSC · Contact · alberto.camuccio@iov.veneto.it · + 39 3336173150
    • Elena Reginato, MSN · Contact · elena.reginato@iov.veneto.it
    • Carlo Alberto Camuccio, MSN; MSC · Principal investigator
    • Orejeta Diamanti, MSN · Sub investigator
    • Camilla zanotto, MSN · Sub investigator
    • Elena Groff, MSC · Sub investigator
    • Elena Reginato, MSN · Sub investigator
    • Sara Craia, BSN · Sub investigator
07

References and documents

Publications

  • Destrebecq A, Ferrara P, Frattini L, Pittella F, Rossano G, Striano G, Terzoni S, Gambini O. The Italian Version of the Opening Minds Stigma Scale for Healthcare Providers: Validation and Study on a Sample of Bachelor Students. Community Ment Health J. 2018 Jan;54(1):66-72. doi: 10.1007/s10597-017-0149-0. Epub 2017 Jun 24. PubMed 28647819 ↗
  • Pasere E, O'Hara D, Ballard E, Kilgour C, Holland L. A narrative review of medical and surgical nurses' attitudes and perceptions when caring for patients with a secondary diagnosis of mental illness. Nurse Educ Today. 2025 Aug;151:106684. doi: 10.1016/j.nedt.2025.106684. Epub 2025 Mar 20. PubMed 40168912 ↗
  • Kisely S, Sadek J, MacKenzie A, Lawrence D, Campbell LA. Excess cancer mortality in psychiatric patients. Can J Psychiatry. 2008 Nov;53(11):753-61. doi: 10.1177/070674370805301107. PubMed 19087469 ↗
  • Ivankova, N. V., Creswell, J. W., & Stick, S. L. (2006). Using mixed-methods sequential explanatory design: From theory to practice. Field methods, 18(1),
  • Giandinoto JA, Stephenson J, Edward KL. General hospital health professionals' attitudes and perceived dangerousness towards patients with comorbid mental and physical health conditions: Systematic review and meta-analysis. Int J Ment Health Nurs. 2018 Jun;27(3):942-955. doi: 10.1111/inm.12433. Epub 2018 Feb 5. PubMed 29399940 ↗
  • Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, Allan S, Caneo C, Carney R, Carvalho AF, Chatterton ML, Correll CU, Curtis J, Gaughran F, Heald A, Hoare E, Jackson SE, Kisely S, Lovell K, Maj M, McGorry PD, Mihalopoulos C, Myles H, O'Donoghue B, Pillinger T, Sarris J, Schuch FB, Shiers D, Smith L, Solmi M, Suetani S, Taylor J, Teasdale SB, Thornicroft G, Torous J, Usherwood T, Vancampfort D, Veronese N, Ward PB, Yung AR, Killackey E, Stubbs B. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019 Aug;6(8):675-712. doi: 10.1016/S2215-0366(19)30132-4. Epub 2019 Jul 16. No abstract available. PubMed 31324560 ↗
  • Elliott K, Haworth E, Bolnykh I, McAllister-Williams RH, Greystoke A, Todd A, Sharp L. Breast cancer patients with a pre-existing mental illness are less likely to receive guideline-recommended cancer treatment: A systematic review and meta-analysis. Breast. 2025 Feb;79:103855. doi: 10.1016/j.breast.2024.103855. Epub 2024 Dec 7. PubMed 39708443 ↗
  • Creswell JW, Inoue M. A process for conducting mixed methods data analysis. J Gen Fam Med. 2024 Oct 3;26(1):4-11. doi: 10.1002/jgf2.736. eCollection 2025 Jan. PubMed 39776872 ↗
  • Charlesworth L, Fegan C, Ashmore R. How does severe mental illness impact on cancer outcomes in individuals with severe mental illness and cancer? A scoping review of the literature. J Med Imaging Radiat Sci. 2023 Jun;54(2S):S104-S114. doi: 10.1016/j.jmir.2023.01.007. Epub 2023 Feb 15. PubMed 36804013 ↗

Study documents

  • Study protocol · May 12, 2026

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — Due to the nature of the study and the need to protect participant confidentiality, individual participant data will not be shared. Results will be reported only in aggregated and anonymised form.

08

Registry details

Key details

Study ID
NCT07748221
Lead sponsor
Istituto Oncologico Veneto IRCCS
Collaborators
Centro di Riferimento Oncologico - Aviano, Istituti Tumori Giovanni Paolo II, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, IRCCS Centro di Riferimento Oncologico della Basilicata
Responsible party
Sponsor
First posted
Aug 5, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Sep 16, 2026

Study contacts

Carlo Alberto Camuccio, MSN; MSC
Contact
alberto.camuccio@iov.veneto.it
+39 3336173150
Angela Grassi, PhD
Contact
angela.grassi@iov.veneto.it
+39 498215527
Carlo Alberto Camuccio, MSN; MSC
principal investigator · Istituto Oncologico Veneto - IOV IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion